Skip to main content
. Author manuscript; available in PMC: 2024 Apr 30.
Published in final edited form as: Curr Opin Virol. 2022 Sep 27;56:101260. doi: 10.1016/j.coviro.2022.101260

Table 1.

Selection of completed and ongoing EBV vaccine trials

NIH Clinical Trials Identifier Vaccine platform EBV antigen Dose and route application Outcome measures Results Status as of January, 2022
NCT04645147 Ferritin nanoparticle gp350 3 doses, i.m. IM Ab and CD4+ to gp350 pending Recruiting
NCT05164094 mRNA gH, gL, gp220 3 doses, i.m. IM Immune response pending Recruiting
NCT00430534 recombinant gp350 3 doses, i.m. IM Immune response, development of IM, seroconversion prevents IM, does not prevent asymptomatic infection Completed (Phase II; Sokal, 2007)
NCT01094405 MVA EBNA1/LMP1 3 doses, i.d. NPC Stable disease, immune response, survival Increased CD4+, CD8+, and Ab Completed (Phase I; Hui 2013))